<DOC>
	<DOCNO>NCT00975182</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study ass safety , tolerability , pharmacokinetics ( PK ) oral ( PO ) GDC-0941 administer combination PO erlotinib patient advance solid tumor patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) fail least one prior chemotherapy regimen .</brief_summary>
	<brief_title>A Study Safety Pharmacology GDC-0941 Combination With Erlotinib Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Documented locally advanced metastatic solid tumor standard therapy either exist proven ineffective intolerable ( doseescalation stage ) Documented locally advanced metastatic NSCLC patient fail least one prior chemotherapybased regimen incurable disease ( cohortexpansion stage ) Adequate organ function assess laboratory test Evaluable disease disease measurable per Response Evaluation Criteria Solid Tumors ( RECIST ) Agreement use effective form contraception duration study Any anticancer therapy ( e.g. , chemotherapy , biologic therapy , hormonal therapy ) within specify timeframe prior first study treatment Prior treatment PI3K pathwayinhibiting agent ( cohortexpansion stage ) History Grade &gt; = 3 fast hyperglycemia diabetes require regular medication Current clinically significant uncontrolled systemic disease ( e.g. , cardiovascular , pulmonary , metabolic ) History clinically significant cardiac pulmonary dysfunction History malabsorption syndrome condition would interfere enteral absorption Clinically significant history liver disease Any condition require fulldose anticoagulant , warfarin , heparin , thrombolytic agent Active autoimmune disease and/or need corticosteroid therapy Known brain metastasis untreated , symptomatic , require therapy Pregnancy , lactation , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PI3K</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Tarceva</keyword>
</DOC>